Sam Brusco, Associate Editor06.13.23
Biotronik has achieved the first implantation of its BIOMONITOR IV implantable cardiac monitor (ICM). The procedure was performed by Luigi Di Biase, MD, Ph.D., Section Head of Electrophysiology, Director of Arrhythmia Services, and Professor of Medicine at Montefiore Einstein in the Bronx, N.Y.
The BIOMONITOR IV ICM pairs Biotronik’s SmartECG tech with artificial intelligence (AI) to reduce false positive detections by 86%, while preserving 98% of true episodes. According to the company, it’s the only ICM able to distinguish between premature atrial contractions (PACs) and premature ventricular contractions (PVCs) to offer better tools for risk stratification and diagnosis.
"I am excited about BIOMONITOR IV's new algorithm and artificial intelligence," Dr. Di Biase told the press. "The data shows that these new features have the potential to reduce false positive alerts for our patients and allow us to focus on actionable events, providing more efficient care."
BIOMONITOR IV also features a long battery life and wireless connectivity to enable data transmission and remote monitoring. Biotronik also provides electronic health record (EHR) compatibility.
Biotronik earned U.S. Food and Drug Administration (FDA) approval for the BIOMONITOR IV ICM in May. It was debuted at the Heart Rhythm Society Congress 2023.
The BIOMONITOR IV ICM pairs Biotronik’s SmartECG tech with artificial intelligence (AI) to reduce false positive detections by 86%, while preserving 98% of true episodes. According to the company, it’s the only ICM able to distinguish between premature atrial contractions (PACs) and premature ventricular contractions (PVCs) to offer better tools for risk stratification and diagnosis.
"I am excited about BIOMONITOR IV's new algorithm and artificial intelligence," Dr. Di Biase told the press. "The data shows that these new features have the potential to reduce false positive alerts for our patients and allow us to focus on actionable events, providing more efficient care."
BIOMONITOR IV also features a long battery life and wireless connectivity to enable data transmission and remote monitoring. Biotronik also provides electronic health record (EHR) compatibility.
Biotronik earned U.S. Food and Drug Administration (FDA) approval for the BIOMONITOR IV ICM in May. It was debuted at the Heart Rhythm Society Congress 2023.